[{"address1": "910 Clopper Road", "address2": "Suite 201S", "city": "Gaithersburg", "state": "MD", "zip": "20878", "country": "United States", "phone": "240 654 1450", "website": "https://altimmune.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.", "fullTimeEmployees": 59, "companyOfficers": [{"maxAge": 1, "name": "Dr. Vipin K. Garg Ph.D.", "age": 66, "title": "President, CEO & Director", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 992999, "exercisedValue": 0, "unexercisedValue": 1959778}, {"maxAge": 1, "name": "Dr. M. Scot Roberts Ph.D.", "age": 65, "title": "Chief Scientific Officer", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 648960, "exercisedValue": 0, "unexercisedValue": 290514}, {"maxAge": 1, "name": "Dr. Matthew Scott Harris AGAF, FCAP, M.D., MS", "age": 71, "title": "Chief Medical Officer", "yearBorn": 1953, "fiscalYear": 2024, "totalPay": 690737, "exercisedValue": 0, "unexercisedValue": 709666}, {"maxAge": 1, "name": "Mr. Gregory L. Weaver CPA, M.B.A.", "age": 68, "title": "Chief Financial Officer", "yearBorn": 1956, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Shutterly M.S.", "age": 35, "title": "Principal Financial & Accounting Officer and Corporate Controller", "yearBorn": 1989, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bertrand  Georges Ph.D.", "title": "Chief Technology Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tony  Blandin B.S.", "title": "Vice President of Quality & Compliance Management", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Raymond M. Jordt M.B.A.", "age": 51, "title": "Chief Business Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 578850, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 4, "compensationRisk": 10, "shareHolderRightsRisk": 4, "overallRisk": 7, "governanceEpochDate": 1740787200, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://ir.pharmathene.com/phoenix.zhtml?c=191999&p=irol-irhome", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 5.2, "open": 5.4, "dayLow": 5.355, "dayHigh": 6.04, "regularMarketPreviousClose": 5.2, "regularMarketOpen": 5.4, "regularMarketDayLow": 5.355, "regularMarketDayHigh": 6.04, "exDividendDate": 1484870400, "payoutRatio": 0.0, "beta": 0.855, "forwardPE": -4.0272107, "volume": 11995647, "regularMarketVolume": 11995300, "averageVolume": 2609110, "averageVolume10days": 3801200, "averageDailyVolume10Day": 3801200, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 455921088, "fiftyTwoWeekLow": 5.14, "fiftyTwoWeekHigh": 11.16, "priceToSalesTrailing12Months": 22796.055, "fiftyDayAverage": 6.4975, "twoHundredDayAverage": 6.968675, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 325710848, "profitMargins": 0.0, "floatShares": 76345950, "sharesOutstanding": 77013696, "sharesShort": 21665305, "sharesShortPriorMonth": 23319504, "sharesShortPreviousMonthDate": 1738281600, "dateShortInterest": 1740700800, "sharesPercentSharesOut": 0.28129998, "heldPercentInsiders": 0.00827, "heldPercentInstitutions": 0.53676, "shortRatio": 9.88, "shortPercentOfFloat": 0.2836, "impliedSharesOutstanding": 77013696, "bookValue": 1.707, "priceToBook": 3.4680727, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -95059000, "trailingEps": -1.34, "forwardEps": -1.47, "lastSplitFactor": "1:30", "lastSplitDate": 1536883200, "enterpriseToRevenue": 16285.543, "enterpriseToEbitda": -3.164, "52WeekChange": -0.34801763, "SandP52WeekChange": 0.09506309, "quoteType": "EQUITY", "currentPrice": 5.92, "targetHighPrice": 28.0, "targetLowPrice": 12.0, "targetMeanPrice": 22.375, "targetMedianPrice": 25.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 131891000, "totalCashPerShare": 1.713, "ebitda": -102934000, "totalDebt": 1681000, "quickRatio": 12.897, "currentRatio": 13.112, "totalRevenue": 20000, "debtToEquity": 1.361, "revenuePerShare": 0.0, "returnOnAssets": -0.36853, "returnOnEquity": -0.59860003, "grossProfits": -82206000, "freeCashflow": -44867124, "operatingCashflow": -79848000, "revenueGrowth": -0.865, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -4973.2, "financialCurrency": "USD", "symbol": "ALT", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Altimmune, Inc.", "longName": "Altimmune, Inc.", "regularMarketChangePercent": 13.846159, "regularMarketPrice": 5.92, "corporateActions": [], "postMarketTime": 1741996791, "regularMarketTime": 1741982400, "exchange": "NGM", "messageBoardId": "finmb_4866807", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "earningsTimestampStart": 1746621000, "earningsTimestampEnd": 1747053000, "earningsCallTimestampStart": 1740663000, "earningsCallTimestampEnd": 1740663000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.34, "epsForward": -1.47, "epsCurrentYear": -1.18645, "priceEpsCurrentYear": -4.989675, "fiftyDayAverageChange": -0.57749987, "fiftyDayAverageChangePercent": -0.088880315, "twoHundredDayAverageChange": -1.0486751, "twoHundredDayAverageChangePercent": -0.15048413, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.7 - Buy", "cryptoTradeable": false, "marketState": "CLOSED", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1495805400000, "postMarketChangePercent": 1.69088, "postMarketPrice": 6.0201, "postMarketChange": 0.1001, "regularMarketChange": 0.72000027, "regularMarketDayRange": "5.355 - 6.04", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 2609110, "fiftyTwoWeekLowChange": 0.7800002, "fiftyTwoWeekLowChangePercent": 0.15175101, "fiftyTwoWeekRange": "5.14 - 11.16", "fiftyTwoWeekHighChange": -5.24, "fiftyTwoWeekHighChangePercent": -0.46953404, "fiftyTwoWeekChangePercent": -34.80176, "dividendDate": 1536883200, "earningsTimestamp": 1740657600, "displayName": "Altimmune", "trailingPegRatio": null, "__fetch_time": "2025-03-15"}]